Olema Oncology Inc. (OLMA)
NASDAQ: OLMAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OLMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $615.00M
- EPS (TTM)
- -$2.40
- Dividend yield
- None
- 52-week range
- 6.24 – 36.26
- Day range
- 6.88 – 7.35
- Volume / Avg
- 1.26M / 1.27M
- Beta
- —
- Shares outstanding
- 87.61M
52-week range
OLMA stock today
On Nov 20, OLMA ended the session at $7.02, shedding $0.13 (1.82%), versus the S&P 500's 3.70% decline. Shares are 80.6% below their 52-week high of $36.26, set on Dec 16, 2025 and 12.6% above the 52-week low of $6.24, near the bottom of the past year's range. OLMA is down 71.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.7%.
Olema Oncology has posted a net loss over the last twelve months (EPS of -$2.40), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Olema Oncology
Company profileOlema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Sean P. Bohen M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 131
- IPO year
- 2020
- Website
- olema.com
Financial highlights
Full financialsOlema Oncology reported a net loss of $162.5 million, compared with a loss of $129.5 million a year earlier. Diluted earnings per share came in at -$1.87.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-162.45M | $-129.47M | $-96.66M | $-104.79M | $-71.10M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$35.50+405.70%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.73 vs $-0.60
- Surprise
- -21.67%
OLMA news
All OLMA news- Olema Reports Promising Early Results For New Breast Cancer Drug CandidatesNasdaqOLMA, BF.A
- Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR SymposiumGlobeNewswire
- Olema Oncology to Participate in Upcoming Investor ConferencesGlobeNewswire
- Commit To Purchase Olema Oncology At $5, Earn 27% Using OptionsNasdaq
- Olema Oncology Announces Corporate Name ChangeGlobeNewswire
- Olema Pharmaceuticals GAAP EPS of -$0.73 misses by $0.10Seeking Alpha
- Olema Oncology Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswire
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Olema Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs OLMA |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs OLMA |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs OLMA |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs OLMA |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs OLMA |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs OLMA |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs OLMA |
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs OLMA |
Indexes, lists and sector
Olema Oncology stock FAQ
What is Olema Oncology's stock price today?
OLMA last traded at $7.02 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.
Who is Olema Oncology's CEO?
Dr. Sean P. Bohen M.D., Ph.D. is the chief executive officer of Olema Oncology Inc., which has about 131 employees.
What is the OLMA 52-week high?
The 52-week high for OLMA is $36.26 and the 52-week low is $6.24. The stock is currently 80.6% below its high.